Theratechnologies (TSX:TH) Notes Receivable : C$0.0 Mil (As of Aug. 2024)

View and export this data going back to 1998. Start your Free Trial

What is Theratechnologies Notes Receivable?

Theratechnologies's Notes Receivable for the quarter that ended in Aug. 2024 was C$0.0 Mil.

Theratechnologies Notes Receivable Historical Data

The historical data trend for Theratechnologies's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theratechnologies Notes Receivable Chart

Theratechnologies Annual Data

Trend

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Nov23

Notes Receivable

Get a 7-Day Free Trial

Theratechnologies Quarterly Data
	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24
Notes Receivable	Get a 7-Day Free Trial															-	-	-	-	-

Theratechnologies Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Theratechnologies Notes Receivable Related Terms

Thank you for viewing the detailed overview of Theratechnologies's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Theratechnologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theratechnologies Inc (TSX:TH) » Definitions » Notes Receivable

Comparable Companies

Traded in Other Exchanges

THTX:USA TQ80:Germany TQ80:Germany

Address

2015, rue Peel, 11th Floor, Montreal, QC, CAN, H3A 1T8

Website

https://www.theratech.com

Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.

Executives

Dale Weil	Director
Joseph Arena	Director
Philippe Dubuc	Senior Officer
Gérald A. Lacoste	Director
Paul Lévesque	Senior Officer
Andrew Molson	Director
Dawn Svoronos	Director
John Leasure	Senior Officer
Alain Trudeau	Director
Sheila Frame	Director
Gary Peter Littlejohn	Director
Marie-noël Colussi	Senior Officer
Jovan Antunovic	Senior Officer
Christian Marsolais	Senior Officer
Jocelyn Lafond	Senior Officer